An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
Phase of Trial: Phase IV
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Idelalisib (Primary)
- Indications Lymphoma
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 04 Jan 2018 Status changed from active, no longer recruiting to completed.
- 29 Aug 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
- 29 Aug 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.